FDA approves Xolair – a breakthrough in food allergy treatment

In a groundbreaking move, FDA has approved Xolair as the first medicine for reducing allergic reactions to multiple food allergens in patients aged one year and older, a decision influenced by the results of the NIH-sponsored Phase III OUtMATCH study. Rho is proud to have been a part of this achievement in food allergy research. 

For more information about the study, read the press release here.